Viroclinics-DDL Diagnostic Laboratory participates in global surveillance programs to monitor and characterize novel virus threats to human and animal health (EMPERIE; EU FP-7). Additional research programs focus on genomics, discovery of biomarkers, correlates of protection and viral reference strain development. A recent example of a newly discovered virus Viroclinics participated in is the MERS Coronavirus. Furthermore, our scientists were at forefront of the discovery of hMPV in 2001 and SARS in 2003.
Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials
Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network
Viroclinics Biosciences B.V.